OPKO Health (NASDAQ:OPK) Downgraded to “Sell” Rating by StockNews.com

OPKO Health (NASDAQ:OPK) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Other research analysts also recently issued research reports about the stock. Piper Sandler restated an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th.

OPKO Health Trading Down 3.3 %

OPKO Health stock opened at $1.48 on Wednesday. OPKO Health has a one year low of $0.86 and a one year high of $1.76. The business’s fifty day moving average is $1.54 and its 200 day moving average is $1.50. The stock has a market capitalization of $1.01 billion, a PE ratio of -7.79 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $1.59 per share, for a total transaction of $198,750.00. Following the completion of the transaction, the chief executive officer now directly owns 212,536,477 shares in the company, valued at $337,932,998.43. This represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders bought a total of 1,304,255 shares of company stock worth $2,024,605 over the last three months. 47.26% of the stock is currently owned by company insiders.

Institutional Trading of OPKO Health

Institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP grew its position in shares of OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares during the period. Squarepoint Ops LLC bought a new position in shares of OPKO Health during the second quarter valued at approximately $592,000. BNP Paribas Financial Markets raised its stake in OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares in the last quarter. Finally, Barclays PLC lifted its holdings in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after buying an additional 329,870 shares during the period. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.